Ardsley Advisory Partners trimmed its position in Clovis Oncology Inc (NASDAQ:CLVS) by 7.1% in the fourth quarter, Holdings Channel reports. The fund owned 104,500 shares of the biopharmaceutical company’s stock after selling 8,000 shares during the period. Clovis Oncology makes up approximately 0.9% of Ardsley Advisory Partners’ investment portfolio, making the stock its 26th largest position. Ardsley Advisory Partners’ holdings in Clovis Oncology were worth $7,106,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. HBK Investments L P increased its holdings in shares of Clovis Oncology by 215.4% in the 4th quarter. HBK Investments L P now owns 84,106 shares of the biopharmaceutical company’s stock valued at $5,719,000 after acquiring an additional 57,442 shares during the last quarter. HealthCor Management L.P. increased its holdings in shares of Clovis Oncology by 50.4% in the 4th quarter. HealthCor Management L.P. now owns 973,840 shares of the biopharmaceutical company’s stock valued at $66,221,000 after acquiring an additional 326,420 shares during the last quarter. Two Sigma Advisers LP bought a new stake in shares of Clovis Oncology in the 4th quarter valued at approximately $3,291,000. Franklin Resources Inc. increased its holdings in shares of Clovis Oncology by 13.8% in the 4th quarter. Franklin Resources Inc. now owns 2,634,401 shares of the biopharmaceutical company’s stock valued at $179,138,000 after acquiring an additional 318,931 shares during the last quarter. Finally, University of Notre Dame DU Lac increased its holdings in shares of Clovis Oncology by 9.5% in the 4th quarter. University of Notre Dame DU Lac now owns 39,989 shares of the biopharmaceutical company’s stock valued at $2,719,000 after acquiring an additional 3,460 shares during the last quarter.
Clovis Oncology Inc (NASDAQ:CLVS) opened at $62.12 on Monday. Clovis Oncology Inc has a 12-month low of $45.42 and a 12-month high of $99.45. The stock has a market capitalization of $3,040.00, a P/E ratio of -14.65 and a beta of 1.10. The company has a debt-to-equity ratio of 0.77, a quick ratio of 7.35 and a current ratio of 7.69.
In other Clovis Oncology news, Director Thorlef Spickschen sold 4,500 shares of the business’s stock in a transaction on Thursday, March 8th. The stock was sold at an average price of $61.47, for a total transaction of $276,615.00. Following the completion of the transaction, the director now owns 12,118 shares in the company, valued at approximately $744,893.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $64.16, for a total value of $192,480.00. Following the transaction, the insider now owns 182,583 shares of the company’s stock, valued at approximately $11,714,525.28. The disclosure for this sale can be found here. Insiders have sold a total of 22,500 shares of company stock valued at $1,371,210 in the last quarter. 12.50% of the stock is currently owned by insiders.
A number of equities research analysts have recently weighed in on CLVS shares. ValuEngine upgraded Clovis Oncology from a “sell” rating to a “hold” rating in a report on Friday, December 29th. Barclays set a $85.00 price target on Clovis Oncology and gave the company a “buy” rating in a report on Tuesday, February 27th. BidaskClub upgraded Clovis Oncology from a “strong sell” rating to a “sell” rating in a report on Saturday, December 9th. Zacks Investment Research upgraded Clovis Oncology from a “sell” rating to a “hold” rating in a report on Wednesday, February 21st. Finally, Stifel Nicolaus reduced their price objective on Clovis Oncology from $125.00 to $110.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $87.84.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology Inc (NASDAQ:CLVS).
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.